Pharmesis International Ltd.: Interim Profit Guidance for 1HFY25
Pharmesis International Ltd. has issued a profit guidance regarding its unaudited condensed interim financial statements for the six months ended 30 June 2025 (1HFY25). The announcement provides an early indication of the Group’s financial performance, which is relevant for existing and prospective investors.
Key Financial Metrics and Performance Overview
The Board of Directors has stated that, following a preliminary assessment, the Group expects to report a net loss for 1HFY25. No specific figures for revenue, earnings per share (EPS), or other financial metrics have been disclosed at this stage. The finalised financial results are pending and will be announced in due course.
| Metric |
Current Period (1HFY25) |
Previous Period |
YoY Change |
QoQ Change |
| Net Profit/Loss |
Expected Net Loss |
Not Disclosed |
Not Disclosed |
Not Disclosed |
Chairman’s Statement and Board Commentary
The announcement is signed by Wu Xuedan, Executive Director and Chief Executive Officer. The Board has adopted a cautious tone, advising shareholders and investors to exercise caution when dealing in the Company’s shares. They recommend consulting professional advisers if there is any uncertainty regarding investment actions. Direct quote from the Board:
“The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.”
Exceptional Items, Asset Revaluation, and Corporate Actions
There is no mention of exceptional earnings or expenses, asset revaluations, share buybacks, fundraising, divestments, mergers, restructuring, or other significant corporate actions in the current guidance. Similarly, no reference is made to changes in directors’ remuneration, legal disputes, macroeconomic events, or related-party transactions.
Outlook and Events Impacting Performance
The Group is still in the process of finalising its financial results for 1HFY25. The early guidance of an expected net loss is a negative indicator for near-term performance. No forecasts or forward-looking statements have been disclosed beyond the cautionary advice to investors.
Conclusion and Investment Recommendations
Overall Financial Performance & Outlook: The preliminary announcement signals a weak financial outlook for Pharmesis International Ltd. for the first half of FY2025, with the Group set to report a net loss. The Board’s cautionary tone further emphasizes the lack of positive momentum and the uncertainty surrounding the final results.
- If you currently hold the stock: Exercise caution. Consider reviewing your investment thesis and monitor the upcoming financial results closely. Consult with your financial adviser before making any significant decisions.
- If you do not hold the stock: It may be prudent to wait for the full interim financial statements and further clarity on financial performance before considering any investment.
Disclaimer: This article is based strictly on the disclosed content of Pharmesis International Ltd.’s profit guidance. It does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisers before making any investment decisions.
View Pharmesis Intl Historical chart here
